Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$56.78 USD
-0.18 (-0.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.74 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 577 | 748 | 740 | 1,202 | 755 |
Receivables | 73 | 40 | 28 | 23 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 34 | 27 | 16 | 13 | 12 |
Other Current Assets | 48 | 69 | 72 | 58 | 51 |
Total Current Assets | 732 | 884 | 857 | 1,295 | 851 |
Net Property & Equipment | 291 | 260 | 141 | 74 | 44 |
Investments & Advances | 200 | 155 | 294 | 166 | 33 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 211 | 205 | 175 | 176 | 173 |
Deposits & Other Assets | 58 | 17 | 21 | 9 | 3 |
Total Assets | 1,491 | 1,545 | 1,522 | 1,760 | 1,136 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 42 | 43 | 17 | 13 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 196 | 205 | 146 | 108 | 83 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29 | 1 | 8 | 59 | 0 |
Total Current Liabilities | 280 | 261 | 181 | 190 | 103 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 30 | 32 | 33 | 33 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 875 | 880 | 354 | 343 | 315 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,216 | 1,193 | 600 | 605 | 482 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,662 | 3,140 | 2,998 | 2,773 | 2,087 |
Retained Earnings | -3,388 | -2,781 | -2,074 | -1,620 | -1,433 |
Other Equity | 1 | -7 | -1 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 275 | 352 | 923 | 1,154 | 654 |
Total Liabilities & Shareholder's Equity | 1,491 | 1,545 | 1,522 | 1,760 | 1,136 |
Total Common Equity | 275 | 352 | 923 | 1,154 | 654 |
Shares Outstanding | 82.10 | 70.10 | 68.10 | 61.00 | 57.70 |
Book Value Per Share | 3.35 | 5.03 | 13.55 | 18.92 | 11.33 |
Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 764 | 412 | 577 | 442 | 552 |
Receivables | 106 | 100 | 73 | 79 | 71 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 40 | 36 | 34 | 32 | 28 |
Other Current Assets | 55 | 48 | 48 | 46 | 51 |
Total Current Assets | 965 | 596 | 732 | 599 | 702 |
Net Property & Equipment | 279 | 285 | 291 | 297 | 289 |
Investments & Advances | 111 | 157 | 200 | 86 | 72 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 211 | 209 | 211 | 202 | 203 |
Deposits & Other Assets | 54 | 60 | 58 | 28 | 26 |
Total Assets | 1,618 | 1,307 | 1,491 | 1,238 | 1,311 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 60 | 41 | 42 | 33 | 42 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 154 | 149 | 196 | 179 | 168 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 47 | 43 | 29 | 30 | 24 |
Total Current Liabilities | 273 | 246 | 280 | 254 | 244 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 30 | 30 | 30 | 32 | 32 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 857 | 875 | 886 | 891 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,186 | 1,167 | 1,216 | 1,206 | 1,182 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 4,123 | 3,699 | 3,662 | 3,298 | 3,237 |
Retained Earnings | -3,690 | -3,558 | -3,388 | -3,264 | -3,105 |
Other Equity | 2 | 3 | 1 | -2 | -3 |
Treasury Stock | 3 | 3 | 0 | 0 | 0 |
Total Shareholder's Equity | 432 | 140 | 275 | 32 | 129 |
Total Liabilities & Shareholder's Equity | 1,618 | 1,307 | 1,491 | 1,238 | 1,311 |
Total Common Equity | 432 | 140 | 275 | 32 | 129 |
Shares Outstanding | 92.10 | 83.10 | 82.10 | 82.10 | 70.80 |
Book Value Per Share | 4.70 | 1.69 | 3.35 | 0.39 | 1.82 |